[Evaluation of therapeutic methods in myasthenia on the basis of data gathered by the Department of Neurology of the Warsaw Medical School].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000549:Ambenonium Chloride / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy; D002219:Carbamates / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009388:Neostigmine / Q000009:adverse effects / Q000627:therapeutic use; D011044:Poland; D011726:Pyridinium Compounds / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D013934:Thymectomy; D013997:Time Factors
D002219:Carbamates; D007166:Immunosuppressive Agents; D011726:Pyridinium Compounds; D009388:Neostigmine; D000549:Ambenonium Chloride; D011729:Pyridostigmine Bromide
Ocena metod leczenia miastenii na podstawie materiału kliniki neurologicznej w Warszawie.